Dalantercept Monotherapy Study Misses Endpoint

Share this content:
Treatment with single-agent dalantercept had favorable safety profile in recurrent or metastatic head and neck squamous cell carcinoma.
Treatment with single-agent dalantercept had favorable safety profile in recurrent or metastatic head and neck squamous cell carcinoma.

Treatment with single-agent dalantercept had modest activity and a favorable safety profile in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) refractory to platinum-based therapy, according to a study published in Cancer.1

For this phase 2 study (Clinicaltrials.gov Identifier: NCT01458392), investigators enrolled 40 patients and assigned them to receive 80 mg, 0.6 mg/kg, or 1.2 mg/kg of dalantercept subcutaneously every 3 weeks.

The overall response rate 5%, with 35% of patients achieving stable disease. Among patients who received 1.2 mg/kg and 0.6 mg/kg of dalantercept, 44% and 30.8% achieved disease control, respectively. No patients in the 0.6-mg/kg group had a partial response.

Patients with human papillomavirus (HPV)-positive disease had a disease control rate of 55%, versus 20% among those with HPV-negative disease (P = .0392)

Median progression-free survival was 1.4 months (95% CI, 1.3-2.2) and median overall survival was 7.1 months (95% CI, 5.5-11.1). The 1-year overall survival rate was 22.7%.

The most common treatment-related adverse events were anemia, fatigue, peripheral edema, headache, and hyponatremia. Thirteen patients had a serious adverse event; there were no treatment-related deaths.

RELATED: Fixed-dose Pembrolizumab Induces Durable Responses in HNSCC

Given its limited antitumor activity and its manageable safety profile, future studies should evaluate the efficacy of dalantercept in combination with chemotherapy and/or radiotherapy as additional strategies for the treatment of recurrent or metastatic HNSCC.                         

Reference

  1. Jimeno A, Posner MR, Wirth LJ, et al. A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2016 Sep 20. doi: 10.1002/cncr.30317 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters